- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Veteran Cowen biotech analyst Eric Schmidt is joining Allogene Therapeutics, the new CAR-T cancer therapy startup, as its chief financial officer. The formal announcement was made Monday in
a joint statement issued by Allogene and Cowen. Arie Belldegrun, the former Kite Pharma CEO and now co-founder and chairman of Allogene, had been recruiting Schmidt for some time, as
previously reported by STAT in May. Schmidt is one of Wall Street’s longest-tenured biotech research analysts, widely respected and followed for his fundamental, science-based approach to
investment advice. Convincing Schmidt to become CFO is a significant win for Allogene as it grows and advances inevitably toward an initial public offering. STAT+ Exclusive Story Already
have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an
account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe
